717 related articles for article (PubMed ID: 7734314)
21. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
Kimiya K; Naito S; Soejima T; Sakamoto N; Kotoh S; Kumazawa J; Tsuruo T
J Urol; 1992 Aug; 148(2 Pt 1):441-5. PubMed ID: 1353119
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4.
Withoff S; de Vries EG; Keith WN; Nienhuis EF; van der Graaf WT; Uges DR; Mulder NH
Br J Cancer; 1996 Dec; 74(12):1869-76. PubMed ID: 8980384
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin.
Tada Y; Wada M; Migita T; Nagayama J; Hinoshita E; Mochida Y; Maehara Y; Tsuneyoshi M; Kuwano M; Naito S
Int J Cancer; 2002 Apr; 98(4):630-5. PubMed ID: 11920626
[TBL] [Abstract][Full Text] [Related]
24. Modulation of multidrug resistance in a cancer cell line by anti-multidrug resistance-associated protein (MRP) ribozyme.
Hatanaka H; Abe Y; Naruke M; Asai S; Miyachi H; Kawakami T; Nagata J; Kamochi J; Kijima H; Yamazaki H; Scanlon KJ; Ueyama Y; Nakamura M
Anticancer Res; 2001; 21(2A):879-85. PubMed ID: 11396179
[TBL] [Abstract][Full Text] [Related]
25. Acute induction of adriamycin-resistance in human colon carcinoma HT-29 cells exposed to a sublethal dose of adriamycin.
Tomida A; Naito M; Tsuruo T
Jpn J Cancer Res; 1995 Feb; 86(2):224-32. PubMed ID: 7730148
[TBL] [Abstract][Full Text] [Related]
26. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
27. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
28. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias.
Beck J; Handgretinger R; Dopfer R; Klingebiel T; Niethammer D; Gekeler V
Br J Haematol; 1995 Feb; 89(2):356-63. PubMed ID: 7873386
[TBL] [Abstract][Full Text] [Related]
29. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga H; Kumazawa J
Oncol Res; 1998; 10(3):123-32. PubMed ID: 9700723
[TBL] [Abstract][Full Text] [Related]
30. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
[TBL] [Abstract][Full Text] [Related]
31. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E
Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629
[TBL] [Abstract][Full Text] [Related]
32. Resistance to topoisomerase II inhibitors in human glioma cell lines overexpressing multidrug resistant associated protein (MRP) 2.
Matsumoto Y; Tamiya T; Nagao S
J Med Invest; 2005 Feb; 52(1-2):41-8. PubMed ID: 15751272
[TBL] [Abstract][Full Text] [Related]
33. A diagnostic tool for monitoring multidrug resistance expression in human tumor tissues.
Schwarzenbach H
Anal Biochem; 2002 Sep; 308(1):26-33. PubMed ID: 12234460
[TBL] [Abstract][Full Text] [Related]
34. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
[TBL] [Abstract][Full Text] [Related]
35. Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide.
Nielsen D; Maare C; Eriksen J; Litman T; Friche E; Skovsgaard T
Biochem Pharmacol; 2000 Aug; 60(3):353-61. PubMed ID: 10856430
[TBL] [Abstract][Full Text] [Related]
36. Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line.
Gonzalez Manzano R; Versanvoort C; Wright K; Twentyman PR
Eur J Cancer; 1996 Nov; 32A(12):2136-41. PubMed ID: 9014757
[TBL] [Abstract][Full Text] [Related]
37. Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay.
Clifford SC; Thomas DJ; Neal DE; Lunec J
Br J Cancer; 1994 Apr; 69(4):680-6. PubMed ID: 7908215
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells.
Cole SP; Sparks KE; Fraser K; Loe DW; Grant CE; Wilson GM; Deeley RG
Cancer Res; 1994 Nov; 54(22):5902-10. PubMed ID: 7954421
[TBL] [Abstract][Full Text] [Related]
40. BIRICODAR (VX-710; Incel): an effective chemosensitizer in neuroblastoma.
Yanagisawa T; Newman A; Coley H; Renshaw J; Pinkerton CR; Pritchard-Jones K
Br J Cancer; 1999 Jun; 80(8):1190-6. PubMed ID: 10376971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
